Parkinson’s Disease Treatment Pipeline Holds Significant Potential for Patients and Investors

Date: 2016-02-18

The Parkinson’s disease treatment pipeline presents a distinctly more promising landscape than the current market, which is burdened with unmet needs and a lack of disease-modifying drugs.

However, Angel Wong, Senior Analyst for GBI Research, states that the pipeline for the disease is highly active, consisting of 365 programs across all stages of development, and a diverse range of molecular targets.

Wong says: “The Parkinson’s disease treatment pipeline is characterized by a high level of innovation compared to the central nervous system segment and the industry as a whole, with 43% of all pipeline programs with disclosed molecular targets being first-in-class.

“While neuromodulators remain dominant in the pipeline, there are a number of targets which address different pathogenic mechanisms underlying neurodegeneration in Parkinson’s disease. This demonstrates a shift from traditional symptomatic treatments to disease-modifying therapies.”

The analyst adds that as the majority of potentially disease-modifying treatments are in the early stages of development, they are expected to fulfill a huge unmet need in the Parkinson’s disease treatment market in the long term.  

GBI Research’s report also states that there are 94 first-in-class products available for strategic consolidations, meaning a vast number of investment opportunities are available for licensing or co-development deals in Parkinson’s disease therapeutics.

Wong explains: “There is substantial focus on early-stage collaboration in Parkinson’s disease treatment, especially for first-in-class products. This is predominantly driven by growing unmet needs, the current lack of disease-modifying therapies and a desire for risk-sharing.


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample